Mark Kipnes, MD
Enriched profileEndocrinologist (Diabetes & Glandular Disease Clinic) · Diabetes & Glandular Disease Clinic
Mark Kipnes is Endocrinologist (Diabetes & Glandular Disease Clinic) at Diabetes & Glandular Disease Clinic. ClinicalTrials.gov lists 14 registered studies with this person as an investigator.
Data verified 11 Oct 2026
Overview
Updated 15 Oct 2026
Mark Kipnes, MD, is Endocrinologist (Diabetes & Glandular Disease Clinic). The public record shows 96 publications with 7,318 citations (h-index 38), centered on Type 2 Diabetes, Dyslipidemias, Obesity. It also documents an investigator role on 14 registered clinical trials, industry payments reported by 56 companies.
- Top research focus: Type 2 Diabetes
- 14 registered trials on ClinicalTrials.gov
- Open Payments reporting from 56 companies
Generated from the cited public record · current as of 15 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 15 Oct 2026
Listed as an investigator on 14 registered studies on ClinicalTrials.gov. The most recent:
- MiniMed Fit Payload Wear Pediatric Study
Sponsor: Medtronic MiniMed, Inc.
- CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
Sponsor: COUR Pharmaceutical Development Company, Inc.
- A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Sponsor: Zucara Therapeutics Inc.
Industry payments
Updated 15 Oct 2026
56 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Mannkind CorporationProgram year20256 payments
- Sequel Med Tech, LLCProgram year202531 payments
- Corcept TherapeuticsProgram year20257 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
53.2%Statin34.5%Atorvastatin Calcium59%Rosuvastatin Calcium41%Part D≥32 patientsCholesterol absorption inhibitor10.3%Ezetimibe100%Part D≥17 patients+ 1 more class in this area
Metabolism & gastrointestinal
24.1%Biguanide (metformin)17.2%Metformin Hcl Er57%Metformin Hcl43%Part D≥17 patientsSGLT2 inhibitor6.9%Jardiance100%Part D<11 patientsHormonal (systemic)
22.7%l-Thyroxine22.7%Levothyroxine Sodium63%Synthroid37%Part D≥24 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Comparison of Point Accuracy Between Two Widely Used Continuous Glucose Monitoring Systems
Journal of Diabetes Science and Technology
2024
Background & recognition
Updated 15 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medifind.com ↗
- Board certified
Diabetes, Metabolism & Endocrinology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medifind.com ↗
Secondary affiliations
appointments beyond the home institution- Adjunct Associate Professor / Clinical Instructor of Medicine (Endocrinology)
University of Texas Health Science Center at San Antonio
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medifind.com ↗ - TrialNet site lead
Diabetes & Glandular Disease Clinic, PA
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →trialnet.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Jens J. Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Daniel J. Drucker
University of Toronto
Kenneth Cusi, MD
University of Florida College of Medicine